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Abstract
Background: tumor-related methylated dna and cir-
culating  tumor  cells  (CtC)  in  the  peripheral  blood
might be of prognostic importance in breast cancer.
thus,  the  aim  of  our  study  was  to  examine  free
methylated dna and CtC in the blood from breast
cancer patients and to correlate it with clinicopatho-
logical features known to influence prognosis. 
Materials  and  Methods:  we  prospectively  obtained
serum  samples  from  85  patients  with  breast  cancer
and  22  healthy  volunteers.  Sera  were  analysed  by
methylation specific PCR (Methylight PCR) for five
genes: adenomatous polyposis coli (aPC), ras associa-
tion domain family protein 1a (RaSSf1a), estrogen
receptor 1 (ESR1), CdKn2a (p16) and glutathione s-
transferase pi 1 (GStP1). Beta actin (aCtB) served as
control. In parallel matched peripheral blood of 63 pa-
tients was used to assay for circulating tumor cells in
the peripheral blood by a modified immunomagnetic
adnatest BreastCancerSelect with PCR detection for
EPCaM, MuC1, MGB1 and SPdEf.
Results:  we  found  a  hypermethylation  in  the  aPC
gene in 29% (25/85), in RaSSf1a in 26% (22/85), in
GStP1 in 18% (14/76) and in ESR1 in 38% (32/85)
of all breast cancer patients. no hypermethylation of
CdKn2a was found (0/25).  Blood samples of pa-
tients were defined CtC positive by detecting the EP-
CaM  13%  (8/63),  MuC1  16%  (10/63),  MGB  9%
(5/55), SPdEf 12% (7/58) and in 27% detecting one
or more genes (15/55). a significant difference was
seen in methylated aPC dna between cancer patients
and  healthy  volunteers.  Moreover,  methylated  aPC,
RaSSf1  and  CtC  were  significantly  different  in
metastatic versus non-metastatic disease. In addition,
the presence of methylated aPC, RaSSf1a and CtC
correlated significantly with aJCC-staging (p = 0.001,
p = 0.031 and 0.002, respectively). High incidences of
methylations were found for the genes RaSSf1 and
ESR1 in healthy individuals (both 23% 5/22). Methy-
lated GStP1 was predominantly found in the serum
of patients with large primaries (p = 0.023) and was
highly significantly correlated with positive Her2/neu
status (p = 0.003). Elevated serum Ca15.3 was strong-
ly correlated with methylated aPC and CtC detection
(both p = 0.000). Methylated ESR1 failed to exhibit
significant  correlations  with  any  of  the  above  men-
tioned parameters. the presence of CtC in peripheral
blood  was  significantly  associated  with  methylated
aPC (p = 0.012) and methylated GStP1 (p = 0.001).
Conclusion:  the  detection  of  methylated  aPC  and
GStP1 dna in serum correlated with the presence of
CtC  in  the  blood  of  breast  cancer  patients.  Both
methylated dna and CtC correlated with a more ag-
gressive tumor biology and advanced disease. 
Key  words:  methylated genes, circulating tumor cells,
circulating dna, breast cancer 
Abbreviations: BC = breast cancer, CtC = circulating
tumor cells, aPC = adenomatous polyposis coli, ESR1
= estrogen receptor 1; RaSSf1a = ras association do-
main family protein 1a, GStP1 = gluthation-s-trans-
ferase pi 1, aCtB = beta actin, MuC1 = Mucin 1,
Ca15.3  =  Cancer  antigen  15.3  (=  MuC1),  MGB1
= Mammoglobin 1 (= SCGB2a2), EPCaM = epithe-
lial cell adhesion molecule, CdKn2a = cyclin-depen-
dent  kinase  inhibitor  2a  (=  p16),  SPdEf  =  SaM
pointed  domain  containing  ets  transcription  factor,
Her-2/neu = ERBB2 human epidermal growth recep-
tor 2, fd = first diagnosis; Rd = recurrence disease,
HR = hormone receptor status, Min-1 = at least one
of  the  gene-complex  (aPC,  RaSSf1a,  GStP1)
methylated, Min-2 = at least two of the gene-complex
(aPC, RaSSf1a, GStP1) methylated, Ct = Rt-PCR
Cycle threshold value
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Haematogenous  dissemination  of  tumor  cells  is  the
main mechanism for distant metastasis and the leading
cause of cancer-related death in breast cancer (BC).
However, early spread of tumor cells usually remains
undetected even by high-resolution imaging technolo-
gies.  Currently,  it  is  still  not  possible  to  accurately
identify  BC  patients  with  a  high  potential  for  a
metastatic disease. therefore, the assessment of indi-
vidual risk factors remains of great importance and
could help in the decision support for a more tailored
treatment approach in the near future. as such, the de-
velopment  of  new  molecular  staging  methods  en-
abling systemic tumor cell spreading might represent a
highly desirable approach for individual tumor therapy
[1]. tumor cells entering the circulation depend on the
organ microenvironment in order to be able to colo-
nize  tissues  and  to  proliferate  [2-6].  one  of  the
promising markers for a current risk classification sys-
tem is the presence of circulating tumor cells (CtC) in
the  blood  of  tumor  patients  [7]  .  Braun  et  al.  [8]
showed that the presence of micrometastasis in the
bone marrow at the time of diagnosis of BC is an in-
dependent predictor of poor prognosis. also Benoy et
al. [9] described the presence of CK19+ disseminated
tumor cells in the bone marrow by reverse transcrip-
tase-PCR as an independent prognostic factor in un-
treated patients with BC [9-11]. In other studies the
persistence of CtC after therapy showed a strong as-
sociation with prognosis, particularly in women with
hormone receptor-negative disease and adjuvant ther-
apy [7].
altered  gene  expression  is  held  responsible  for  a
transformed behaviour of tumor tissue [12, 13, 14, 15]
and may distinguish tumor from healthy cells [16-17].
However, it remains unclear which genes allow a spe-
cific  detection  of  malignancy.  Epigenetic  modifica-
tions, such as dna methylation, are one of the most
common  molecular  alterations  in  human  neoplasia
[18-19]. dna methylation refers to the addition of a
methyl group to the cytosine ring of those cytosines
that precede a guanosine (referred to as CpG dinu-
cleotides)  to  form  5-methylcytosine.  CpG  dinu-
cleotides are found at increased frequency in the pro-
moter region of many genes, and their methylation is
frequently associated with gene silencing [20]. of clin-
ical  interest  in  the  view  of  molecular  diagnosis  and
prognosis is the fact, that several studies have shown
tumor-specific epigenetic alterations in the dna re-
covered from plasma or serum of patients with vari-
ous malignancies [21-23]. additionally, increased con-
centrations of free dna are detected in blood of sev-
eral  cancer  patients,  whereas  only  small  amounts  of
free circulating dna are found in healthy individuals
[24]. Gal et al. [25] reported about an average of ap-
proximately four times more free dna in the serum
of breast cancer patients, compared to healthy individ-
uals.  Hypermethylation  of  ras  association  domain
family protein 1a (RaSSf1a), adenomatous polyposis
coli  (aPC)  and/or  ESR1  identified  in  serum  dna
from breast cancer patients was found to be associated
with a worse outcome [26]. furthermore, methylated
RaSSf1a and neurogenic differentiationof gene pro-
moters in serum are candidate biomarkers for moni-
toring the efficacy of adjuvant therapy in breast cancer
patients [27, 28]. although methylated GStP1 dna is
predominately reported as a marker of prostate can-
cer, Papadopoulu et al. [29] demonstrated its predic-
tional impact also in breast cancer. the parallel analy-
sis of different methylated markers takes into account
the inter- individual variations of gene expression and
methylation.
However,  the  mechanism  of  releasing  dna  into
the bloodstream remains unclear. there are hypothesis
of lysis of CtC, dna leakage from cells as the result
of  tumor  necrosis  or  apoptosis,  or  spontaneous  re-
lease of dna into the circulation from primary and
metastatic tumors [30].
the aim of this study was to validate tumor-specific
epigenetic alterations in the cell-free dna found in
the peripheral blood of breast cancer patients and to
assess whether a correlation exists between tumor-spe-
cific methylated dna, CtC and the clinical status of
patients  diagnosed  with  breast  cancer.  a  combined
molecular assessment of the circulating dna as well
as CtC might help to improve the evaluation of can-
cer stage and overall prognosis in breast cancer. thus,
we  examined  the  tumor  associated  aPC,  RaSSf1,
GStP1, ESR1 genes, while aCtB served as a control.
due  to  the  fact  that  elevated  levels  of  methylated
dna have mainly been reported in women with ad-
vanced disease, we decided to investigate these molec-
ular markers in a patient collective with predominate
progressive tumors.
MatERIalS and MEtHodS
PatIEntS and SaMPlE CollECtIon
we prospectively obtained serum samples from 86 pa-
tients with breast cancer and 23 healthy volunteers and
matched  peripheral  blood  from  63  patients.  all  pa-
tients gave informed consent for the study and the ex-
amination of blood samples was carried out after ap-
proval  from  the  Institutional  Review  Board  of  the
university of d￼sseldorf, Germany. 
Blood samples from all patients were taken during
the  course  of  radiotherapy.  the  patient  population
consisted of 65 patients with primary adjuvant therapy
and 21 patients with recurrency and secondary adju-
vant treatment. the clinico-pathological variables are
listed in table 1. Median age of the control population
was 44 (range, 24-61) years and 60 (range, 34-81) years
in the breast cancer population.
ISolatIon of SERuM dna
Blood (4 ml) from each donor was collected in serum
separator  tubes  (Becton  dickinson)  and  centrifuged
(2000g,  15  min)  at  room  temperature.  then,  serum
was aliquotted and cryopreserved at -80ﾰC until use.
for both, normal sera and cancer sera analysis 1 ml
serum  was  used  for  dna  extraction.  the  genomic
dna from serum samples was extracted using the ul-
traSens  virusKit  (QIaGEn,  Hilden,  Germany)  ac-
cording to a modified manufacturer’s protocol. after
the Proteinase-K digestion the dna extract was re-
loaded a second time on the dna extraction columns.
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Hilden, Germany) were added and centrifuged for 1
min  at  6,000  x  g.  a  second  65ﾵl  volume  avE  was
added onto the column and both eluates were pooled.
dna was quantified in triplicate by a real-time quanti-
tative PCR assay “on demand” for the Rnase-P gene
and  compared  to  Rt-PCR  reactions  with  three-fold
serial dilutions of known concentrations of dna as
template (applied Biosystems, foster City, Ca, uSa). 
analySIS of MEtHylatEd dna 
Extracted  dna  samples  were  subjected  to  sodium
bisulphite  conversion  using  the  CpGenome™  dna
Modification Kit (CHEMICon, uSa). Sodium bisul-
phite-converted  dna  was  extracted  in  100  ﾵl  tE-
buffer  analysed  by  a  methylation  specific  real-time
PCR, Methylight (Eads 2000 nucleic acid Research).
Per  Gene  one  set  of  primers  and  probe,  designed
specifically for methylated, sodium bisulphite-convert-
ed dna, were used. a methylation inspecific aCtB
probe (lacking CpG dinucleotides) was used for con-
trol of quality and bisulphite conversion. fluorogenic
(faM/taMRa)  probes  and  PCR  primer  sets  for
aPC,  RaSSf1a,  GStP1,  ESR1,  CdKn2a,  and
aCtB were custom synthesised by Eurogentec (K￶ln,
Germany) according to previous published sequences
[26, 31]. fluorogenic PCRs were carried out in a reac-
tion volume of 15 ﾵl in 384-well plates in a 7900Ht
Sequence  detector  (applied  Biosystems).  PCR  was
carried  out  in  separate  wells  for  each  primer/probe
set, and each sample was run in triplicate. the final re-
action mixture consisted of 600 nmol of each primer,
200 nmol of probe and 7,5 ﾵl of 2xuniversal Master
Mix (applied Biosystems). 4 ﾵl of the treated dna
solution was used in each real-time reaction. Standard
thermal Rt-PCR cycling started with a first denatura-
tion step of 95ﾰC for 10 min. the amplification pro-
file for the PCR was 95ﾰC for 15 s and 60ﾰC for 1 min.
data obtained during 50 cycles of amplification were
analysed. Bisulphite modified dna isolated from nor-
mal peripheral lymphocytes (PBl-dna) served as a
negative  control  and  a  previously  M.Sss1-yMethyl-
transferase methylated PBl-dna (new England Bio-
labs, frankfurt a.M., Germany) was used as the methy-
lation positive control. a gene was deemed methylated
if the threshold cycle number for at least one of three
reactions was below 40 Ct or cycle number for at least
two reactions were below 45 Ct.
Analysis of  CTC in Peripheral Blood 
(Modified AdnaGen-Protocol) 
Blood (5 ml) samples were taken using Edta collec-
tion tubes and immediately placed on ice and further
preceded within 2 hours. for each donor, a modified
adnatest Breast Cancer Select/detect technique was
used on one blood sample, according to the manufac-
turer’s  instructions.  adnatest  Breast  Cancer  Select
BreastSelect  Beads  (adnaGen,  langenhagen,  Ger-
many) (100 ﾵl) were added to 5ml of blood and incu-
bated for 120 min at room temperature (5 r.p.m.). af-
ter incubation, cells were repeatedly washed with PBS
and  lysed  by  adding  a  lysis/Binding  buffer  (adna-
Gen). the supernatant was recovered.
adnatest Breast Cancer detect mRna was subse-
quently  separated  by  a  magnetic  unit  using
oligo(dt)25 dynabeads. the total mRna/bead mix-
ture (29.5 ﾵl) was reverse transcribed using 0.5 ﾵl of
Rnase  inhibitor  (40u/ﾵl;  recombinant  Rnasin,
Promega, Mannheim, deutschland) 4 ﾵl of Rt buffer,
4 ﾵl of dntPs and 2 ﾵl of Reverse transcriptase (Sen-
siscript  transcription  Kit,  Qiagen  GmbH,  Hilden,
deutschland). Reverse transcription was performed in
a one-step reaction (60 min at 37ﾰC, 5 min at 93ﾰC).
the mixture was then chilled down on ice and stored
at -20ﾰC. for the analysis of tumour-associated mR-
nas, a multiplex PCR and a Rt-PCR was carried out. 
Multiplex PCR
the primer mixture consisted of four specific primer
pairs for the amplification of three tumour markers
(Muc-1, HER2 and EPCaM) and one housekeeping
gene (actin). Multiplex PCR analyses were carried out
in a final volume of 50 ﾵl PCR mixture, containing 8
ﾵl of cdna, 4 ﾵl primer mixtures (PrimerMix Breast-
detect; adnaGen), 25 ﾵl of Hot Star taq Master Mix
(Qiagen)  and  13  ﾵl  of  distilled  water.  PCR  analyses
were  performed  as  described  by  the  manufacturer.
negative controls (no template control) and a diluted
mixture of PCR-amplicons (part of adnaGen detect
KIt) were included within each daily setup. PCR am-
plicons were evaluated at adnaGen laB on a dna
1000  labChip  Bioanalyzer  2100  (agilent  technolo-
gies GmbH, B￶blingen, deutschland). Samples with-
out  an  internal  positive  actin  Signal  were  excluded
from  further  analyses.  one  gene  was  considered  as
positively detected if the amplicon concentration was
higher 0,1 ng/ﾵl according to the manufacturer’s vali-
dation. HER2 signals were excluded from analysis be-
cause of high unspecific incidence in healthy donor
reactions (data not shown). 
RT-PCR
two further genes were included in analysis by sepa-
rate Rt-PCR reactions on the 7900Ht Sequence de-
tector (applied Biosystems). the same reaction con-
ditions  were  used  as  for  methyl  specific  PCR  de-
scribed above. Instead of customer designed methyla-
tion specific probes, predesigned cdna specific ex-
pression  probe  sets  were  used.  the  genes  were
SCGB2a2  Hs00267190_m1  (MGB1)  and  SPdEf
Hs00171942_m1  (assays  on  demand,  applied  Bio  -
systems); 2ﾵl of the cdna from the adnaGen detect
Rt-Reaction  were  used  as  template  for  each  gene.
Glucuronidase  [GuS-B]  specific  primer  probe  mix-
ture (Hs99999908_m1) was used as separate control
reaction. a gene was deemed Rt-PCR positive if the
Ct was below 41 cycles.
StatIStICal analySIS
Correlations were checked by Pearson’s two-sided c2 -
test  for  dichotomized  values.  dichotomisation  of
pathological markers based on the following thresh-
olds: >10% cell nuclei stained at least weakly positive
for ER or PR, immunhistochemical Her2/neu score >
2+ and Ca15.3 > 32 u/ml. Pearson linear by linear
association  was  used  for  ordinal  recoded  variables
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pare dichotomized values and non-parametric distrib-
uted variables (dna-level). the level of significance
was determined as p < 0.05. all statistical calculations
were carried out using SPSS, version 12.0 (SPSS Inc,
Chicago, Il, uSa). 
RESultS
total dna ConCEntRatIonS In PlaSMa fRoM
HEaltHy voluntEERS and BREaSt CanCER
PatIEntS
In our study differences between total plasma dna
concentrations  in  BC  patients  and  the  controls
reached  no  statistical  significance  (p  =  0.79).  there
was also no difference in plasma dna concentrations
between  primary  and  recurrent  tumor  patients  (p  =
0.37). 
Plasma dna concentrations failed to associate with
tumor-related  methylated  genes,  circulating  tumor
cells,  estrogen-  and  progesteron  receptor  status,
ERBB2 and clinical status (tnM, whitney u-test). 
tuMoR-RElatEd MEtHylatEd dna In SERuM
In total 29 % of the BC patients showed a hyperme-
thylated aPC gene in comparison to 9% in the control
group (p = 0.050). this was also due when aPC was
compared between primary and recurrent disease (p =
0.006). Hypermethylated dna was detected in 26%
of the BC patients for the RaSSf1 gene, in 18% for
the GStP1 and in 38% for the ESR1 gene with no sig-
nificant  differences  compared  to  the  healthy  group.
the CdKn2a gene was only methylated in one single
volunteer in the control group, which prompted us to
exclude it from further examinations.  
Methylated dna concentrations tended to be cor-
related with tumor progression (table 1). Statistically
significant correlations were observed between t1+t2
vs. t3+t4 for the genes RaSSf1 (p = 0.029), GStP1
(p = 0.000), and in the combination of at least one of
the genes (aPC, RaSSf1a, GStP1) methylated (Min-
1, p = 0,010) and at least two genes (aPC, RaSSf1a,
GStP1) methylated (Min-2, p = 0.004). 
unexpectedly  low  correlations  were  found  when
methylated  dna  status  was  compared  with  lymph
node  status,  tumor  grading,  estrogen-  and  proges-
terone  receptor  status.  However,  methylated  dna
concentrations in aPC (p = 0.002) and RaSSf1 (p =
0.046) significantly correlated with metastatic disease.
GStP1 (p = 0.003) and ESR1 (p = 0.024) methylation
correlated strongly with the Her-2/neu-status, whereas
aPC  methylation  correlated  with  the  Ca-15.3  (p  =
0.000) tumormarker level. RaSSf1 showed a tendency
to a more aberrant methylation in older compared to
younger participants (p = 0.089). a high concordance
was observed between the methylation of aPC and
RaSSf1 and the tnM combining aJCC-Index. table
2 shows the correlation between the hypermetylated
genes,  which  was  strongest  between  aPC  and
RaSSf1a (p = 0.000), while GSt1 gave a more inde-
pendent information. no significant associations were
found  between  the  hypermethylation  of  ESR1  and
GSt1.  
dEtECtIon of CIRCulatIon tuMoR CEllS
due to the relative low incidence of single epithelial
marker  gene  detection  in  immunomagnetic  enriched
cell fraction [13% (8/63) for EPCaM, 16% (10/63)
for MuC1, 9% (5/55) for MGB1, and 13% (8/63) for
SPdEf]  two  indices  were  created.  the  first  index
(CtC-2),  combines  the  adnaGen  marker  EPCaM
and/or  MuC1  and  another  combining  all  four  de-
scribed  epithelial  markers  (CtC-4).  (the  Her2/neu
marker,  which  is  a  third  marker  in  the  andadetect
multiplex PCR, was also positive in 13% (8/63 BC)
cases, but was excluded from analyses because of high
incidence >50% in healthy controls. 19% (12/63) of
BC were positive in the two gene set and 27% (15/55)
of BC were positive in the four gene index. as was
observed  with  methylated  dna  in  serum,  the  two
marker index CtC-2 showed high correlation to the
higher risk groups (high aJCC-Index p = 0.002, pM+
p = 0.009, Ca15.3 positive p = 0.000 and progressive
disease p = 0.050). Moreover, pn+ incidences showed
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Table 1. aJCC-Classification of the patient population. Clin-
ical Staging of 85 breast cancer patients presenting with first
diagnosis (fd) or Recurrence disease (Rd) were enrolled in
this study. t-Stage represents disease staging according to the
american Joint Committee on Cancer.
T-Stage Total FD RD
aJCC (n = 85) (n = 65) (n = 19)
02 2 0
I 18 16 2
IIa 15 15 0
IIb 880
IIIa 321
IIIb 981
Iv 23* 9 13
-** 7** 5** 2**
*1 patient Rd/fd uncertain, **tnM information unavail-
able
Table 2. Correlation of hypermethylation in 4 genes.
APC RASSF1 GSTP1
neg pos neg pos neg pos
ESR1 neg 42 11 44 9 41 7
pos 18 14 19 13 20 7
c2 = 0.024*
c2 = 0.016* c2 = 0.226
APC neg 51 9 44 8
pos 12 13 17 6
c2 = 0.000* c2 = 0,024*
RASSF1 neg 49 7
pos 12 7
c2 = 0.019*
* p < 0.05 
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marker  index  CtC-4  displayed  similar  correlations.
the addition of SPdEf and MGB1 further improved
the contribution to high risk BC detection without in-
creasing the rate of false positives. However, a false
positive background in the healthy controls was ob-
served in CtC- as well as methylated dna detection
methods. 
aSSoCIatIon of CtC and SERuM MEtHylatEd
dna 
the  detection  of  a  methylated  gene  in  the  serum
dna was significantly associated with the detection
of CtC in peripheral blood. the methylated aPC and
GStP1 genes were correlated with each of the four
CtC  parameters,  with  the  exception  of  the  MGB1
marker, which was only positively detected in 5 cases.
EPCaM showed the highest association to methyla-
tion.  over  70%  of  the  patients  with  EPCaM  gene
methylation  were  additionally  positive  detected  for
aPC or GStP1 methylation (both p = 0.001). fur-
thermore, both methylated genes were highly associat-
ed with the CtC marker combining indicies. However,
the methylated genes RaSSf1 and ESR1 failed to dis-
play  significant  correlation  with  the  CtC  detection,
but a correlation to EPCaM  was at least marginal sig-
nificant (p = 0.094, p = 0.087 respectively).  
CoMBInInG of PaRaMEtERS
Combining the different targets of methylated dna
into one score better takes into account the tumor di-
versity.  thus  aPC,  RaSSf1  and  GStP1  were  com-
bined to a Min-1 score. to overcome the high inspeci-
fity rate, a second score Min-2, requiring two hyper-
methylations in the aPC, RaSSf1 and GStP1 set was
recoded. Methylated ESR1 was left out, because of the
high incidence rate in healthy donors and its indepen-
dence from clinical features. the association of both
scores with most clinicopathological features was sig-
nificant. the Min-1 score was deemed positive in 48
% of the BC patients. In healthy volunteers it was de-
tected in 38%. the more stringent index Min-2 was
positive in 20% of BC and was highly associated with
tumor aggressiveness, as indicated by the high correla-
tion with increased Her2/neu, Ca-15.3, tumor size, M-
state and aJCC index. the Min-1 positivity rate was
generally twice as high in the more aggressive clinic
groups (82% in t3+t4 vs. 39% in t1+t2; 67% in
M+ vs. 34% in M0; 73% in recurrent cases vs. 39% in
first  diagnosis.  the  more  stringent  Min-2  score  was
positive in 20% of overall BC, but positive in 42% of
the  aJCC-Iv  high  risk  group  vs.  10%  in  the  lower
groups. the incidence was also significantly six times
increased from 7% in the low Her2 group to 41% in
the Her2 positive group (p = 0.001). the combined
methylation scores failed to reach significance when
compared with the CtC detection, with the exception
of the CtC marker EPCaM (Min-1 p = 0.024, Min-2
p  =  0.005).  we  further  tested  one  CoMBI  score,
which consists of the stringent methylation score Min-
2  and  the  CtC  score  CtC-2  (EPCaM  or  MuC1).
this CoMBI-Score was positive in 35% of all BC cas-
es. 89% of the Ca15.3 positive patients turned out to
be also positive for the CoMBI score, while the lower
risk Ca15.3 negative group was only CoMBI positive
in 21% of all cases (p = 0.000). the incidence of the
CoMBI Score was even elevated in the ER negative
group (50% vs.  28%) in the ER positive group (p =
0.182) and elevated in the Her2 group >2+ (47% vs
24%, p = 0.088). But these associations failed to reach
significance. table 3 lists the significant correlations of
CoMBI with most clinic parameters. 
dISCuSSIon
Haematological CtC are a prerequisite to distant or-
gan metastasis in many cancer entities [7, 32-34]. Sev-
eral studies suggest that only a minority of tumor cells
have the ability to invade and metastasize [35, 36, 37].
therefore, it is crucial to investigate which genes ulti-
mately  facilitate  tissue  invasion  and  disease  progres-
sion.
Circulating dna could be observed in plasma of
healthy persons but was increased in cancer patients
[24]. this knowledge has attracted much attention to
the potential use of circulating free dna as a tumor
marker. In our study, we measured the level of circu-
lating dna in the serum of healthy volunteers and
patients with localised or metastatic breast cancer us-
ing  real-time  quantitative  PCR.  Interestingly,  dna
concentrations  in  BC  patients  and  the  controls
reached no statistical significant difference. there was
also no difference in serum dna concentrations be-
tween primary and recurrent tumor patients. this is
opposed to the results by auwera et al., which found a
3.25-fold difference in the median levels of circulating
total dna in plasma between breast cancer patients
and healthy controls [38]. Methylated dna markers
are  attractive  tumor  markers  in  blood  and  are  fre-
quently found in a wide range of human cancers but
not (or rarely) in healthy controls 22-23, 39-40. they
are not limited to patients with metastatic cancer but
are also present in body fluid from patients with early
or organ-confined tumors 23, 41. In general, a high
concordance between epigenetic alterations in primary
tumor specimens and methylated dna in blood has
been reported [42-45]. 
aPC,  RaSSf1a  and  ESR1  are  known  to  be  fre-
quently hypermethylated in breast cancer [19]. In addi-
tion we examined GStP1 and CdKn2a to provide a
more versatile target for detection in serum [46]. Simi-
lary to M￼ller et al. [26] we measured methylation lev-
els of these genes in serum instead of plasma. Except
CdKn2a, BC patients showed hypermethylation of
the genes. whereas CdKn2a has been reported earli-
er as one of the most methylated genes in breast can-
cer patients, we did not find any CdKn2a methyla-
tion in serum of our study group [47, 48, 19]. M￼ller
et al. [26] did also include CdKn2a in an evaluation
set of 10 recurrent breast cancer sera and failed posi-
tive detection in all 10 cases. ESR1 showed the highest
frequency of hypermethylation with 38% and was fol-
lowed by aPC (29%), RaSSf1a (26%) GStP1 (18%)
and CdKn2a (0%). However, methylation was also
detected in a smaller proportion in the control per-
sons. In this healthy donor group ESR1 and RaSSf1a
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(9%) and GStP1 (6%). So the frequency of methyla-
tion in serum dna of RaSSf1a, GStP1 and ESR1
was  increased  among  women  with  breast  cancer  as
compared to controls, but this tendency reached only
significance for aPC 29% vs. 9% (p = 0.050). auwera
et al. [38] found very similar data for aPC. ESR1 also
failed  to  reach  tumor  specific  significance  in  their
study. the incidence of RaSSf1a methylation in our
control  group  seems  quite  untypical  compared  with
studies of M￼ller [26, 31], but in our study RaSff1a
displays and emphasizes its tumor related importance
by a significant correlation to aJCC Index (p = 0.031),
tumor size (p = 0.029) and metastasis p = 0.046. auw-
era et al. [38] examined two marker expressions and
found aPC an RaSSf1a to be the most frequent de-
tected  combination.  we  found  identical  methylation
status  for  both  markers  in  71%  of  all  cases  (p  =
0.000). M￼ller et al. [31] found a hypermethylation of
RaSSf1a, aPC and ESR1 in a test set of extended
tumor disease (24 patients)  but aPC and ESR1 lost
univariate significance in a trainigsset (62 patients). 
another association was suspected between methy-
lation of specific genes in serum dna and HR status.
widschwendter et al. [19] reported significant differ-
ences  in  the  HR  status  between  clusters  of  dna
methylation profiles. In particular, the methylation of
RaSSf1a in breast cancer has already been associated
to  hormone  regulation.  feng  et  al.  [49]  reported  a
methylation of RaSSf1a with a strong correlation of
estrogen, progesteron and HR expression. they sus-
pected  whether  methylation  of  growth-suppressor
genes would correlate with the expression of estrogen
and progesteron. Moreover, Sunami et al.50 reported
on a hypermethylation of RaSSf1a and a positive es-
trogen status.
In contrast, we found serum dna hypermethyla-
tion of all genes examined to be independent of the
estrogen- and progesteron receptor status. this might
be due to the huge proportion of progressive tumors
in our collective, because Sunami et al-found the recep-
tor dependence of epigenetic alterations predominately
in early stages (t0/t1) of tumor progression [50].
In  our  study  hypermethylation  of  GStP1  and
ESR1  as  well  as  the  combinations  Min-1  or  Min-2
showed a highly significant correlation with the Her-
2/neu-status.  GStP1  methylation  and  Her2/neu ex-
pression  was  previous  examined  by  Shinozaki  et  al.
[51]. GStP1 hypermethylation was more frequent in
the lymph node metastasis positive group than in the
negative group and GStP1 showed the highest corre-
lation to positive Her2/neu status (p = 0.0019). 
In line with these results Jhaveri and Morrow  re-
ported about hypermethylation of GStP1 and a nega-
tive estrogen status [52]. However, this is different to
the studies reported above.
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Table 4. frequencies of methylated genes in association to circulating tumor cells.
* p < 0.05;   ** p < 0.005 high significant
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be observed in peripheral blood of breast cancer pa-
tients. although in patients with primary BC the con-
centration of Ca15.3 can be within normal range, in-
creased  levels  of  Ca15.3  are  often  observed  in  pa-
tients  with  metastatic  disease.  In  our  study  Ca15.3
showed a significant correlation to hypermethylation
in particular with the aPC gene (p = 0.000) while the
other  genes  failed  to  show  correlation  with  Ca15.3.
High correlation of Ca15.3 was also found by auwera
et  al.  [38]  (p  =  0.001).  Controversially  to  our  study
they reported on a similar high correlation of Ca15.3
and RaSSf1a (p<0.001), but like in our study hyper-
methylation of ESR1 was independent from Ca15.3
marker. nearly all patients with elevated Ca.15.3 were
positive for CtC (7/8), p = 0.000). as selected methy-
lation markers, we found positive CtC markers pre-
dominately  present  in  patients  with  positive  lymph
nodes, metastatic tumors progressive disease and high
aJCC  Index.  Similar  to  hypermethylated  dna  in
serum,  CtC  detection  is  not  exclusively  specific  to
breast cancer. In peripheral blood variable numbers of
epithelial cells have been found to be related to benign
epithelial  proliferative  diseases,  inflammation,  tissue
trauma and/or surgical interventions [52-54]. there-
fore cell search systems are exposed for false positive
results using immuno-mediated CtC detection tech-
niques which can occur by specific labelling of non-
tumor epithelial cells or non-specific labelling of non-
tumor  non-epithelial  cells  [55].  further,  the  PCR-
based  tumor  associated  gene  detection  used  in  this
study  might  interfere  with  background  gene  expres-
sion in nearly silenced, but leaky genes. 
up to date, there is no agreement on the mecha-
nisms responsible for the presence of tumor dna in
peripheral blood. However, patients with CtC in pe-
ripheral blood had significantly higher total dna lev-
els  in  plasma  than  patients  with  no  CtC.  although
plasma or serum total dna is measured in many stud-
ies, it has never reached acceptance level as a specific
tumor marker. the more tumor specific, or at least tu-
mor associated feature of genetic or epigenetic dna
modification might display more tumor accordance. 
Especially hypermethylated aPC and GStP1 were
significantly correlated with the CtC detection in pe-
ripheral blood. In contrast to auwera et al. [38] we
found RaSSf1 not associated with CtC. the failure
to detect methylated CdKn2a in 25 BC sera might
be interpreted as a circumstantial evidence, that CtC
do  not  form  the  source  for  free  methylated  serum
dna, because it is methylated in a huge proportion of
breast tumors and should be found to a high extend in
BC sera. Schwarzenbach et al. [56] did not observe a
correlation between the presence of CtC and the loss
of  heterozygosity  in  circulating  dna  in  the  blood
from breast cancer patients But these deviations might
be related to a failure in methodological standardiza-
tion, which is not easily realizable in rare cell detection
and methylation analysis or is related to the low pa-
tient number. 
despite individual differences in the observed cor-
relation  between  CtC  and  circulating  methylated
dna, the correlation could be interpreted as follows:
a) CtC are a potential source of circulating tumor-
specific dna or B) CtC as a parallel maker to free tu-
mor dna. But independent of causal courses, both
makers secondarily correlate with a phenotypic feature
of  a  more  aggressive  tumor  biology.  However,  the
prognostic importance of CtC and serum methylated
dna could not be determined at this time. therefore,
large-scale studies are necessary to validate the clinical
utility of these methods.
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